InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.98
(
0.07%
)
US TECH 100
19,985.60
(
0.38%
)
Dow Jones
39,291.97
(
0.00%
)
Brent Oil
84.26
(
-0.52%
)
Bitcoin
58,505.19
(
0.84%
)
Post# of 705015
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

AngeloFoca

Send PM Follow Ignore
Followers 19
Posts 1187
Boards Moderated 0
Alias Born 05/06/2014

AngeloFoca

Re: flipper44 post# 50387

Tuesday, 01/12/2016 2:24:56 PM

Tuesday, January 12, 2016 2:24:56 PM

Post# of 705015
Present Phase 3 trial is for newly diagnosed GBM.

Do you think the crossover comparator would yield enough information to possibly apply for approval expansion for Recurring GBM???
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News
InvestorsHub NewsWire

Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM

Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM

Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

Start posting your company's news
Only $200 per official company press release!